[Clinical experiences with aminoglutethimide (Elipten), a new inhibitor of steroid biosynthesis in the adrenal gland].
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism*; D000314:Adrenal Rest Tumor / Q000188:drug therapy; D000328:Adult; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use; D000814:Aniline Compounds / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D003480:Cushing Syndrome / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D008297:Male; D011728:Pyridones / Q000627:therapeutic use*; D013256:Steroids / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
D000814:Aniline Compounds; D000927:Anticonvulsants; D011728:Pyridones; D013256:Steroids; D000616:Aminoglutethimide
Klinische Erfahrungen mit Aminoglutäthimid (Elipten), einem neuen Inhibitor der Steroidbiosynthesis in der Nebenniere.